

LEGAL NOTICE

If you purchased Traditional Blood Reagents between November 4, 2000 and October 19, 2015, a class action settlement and distribution of two class action settlement funds may affect you.

This Notice is being sent to you pursuant to an Order of the United States District Court for the Eastern District of Pennsylvania. This is not a solicitation from a lawyer. You are not being sued.

- This Notice describes a class action lawsuit (*In re Blood Reagents Antitrust Litigation*, MDL No. 2081 and 09-MD-2081), pending in the United States District Court for the Eastern District of Pennsylvania, in which Plaintiffs allege that certain manufacturers conspired to fix Traditional Blood Reagents prices in violation of federal antitrust law.
- The lawsuit claims that, as a result of Defendants' alleged conduct, the prices paid by individuals and entities for Traditional Blood Reagents were higher than they otherwise would have been. The lawsuit seeks treble damages (triple the amount of actual damages), attorneys' fees and costs from Defendants. Defendants have denied the allegations of price fixing. Defendants have also denied that they are liable for any damages, attorneys' fees, or costs. The Court has dismissed Plaintiffs' claims regarding Defendants' Traditional Blood Reagents price increases in 2005 and 2008, but it found that Plaintiffs offered sufficient evidence regarding Defendants' alleged conspiracy to fix prices starting in 2001 for Traditional Blood Reagents to proceed to trial against the remaining defendant in the case, Ortho-Clinical Diagnostics, Inc. ("Ortho").
- You may have received prior notices regarding this lawsuit. The purpose of this Notice is to inform you of **two new developments**:
 - A **Settlement** has been entered into with Ortho for \$19.5 million. This Notice provides information about the right to object to that settlement.
 - If the Ortho Settlement is approved, it will **conclude the litigation** and funds from this settlement and a prior settlement with Defendant Immucor, Inc. ("Immucor") will be distributed. This Notice provides information about the **Proposed Distribution** of those funds.

This Notice advises you of your rights – **and the deadline to exercise them** – in connection with the above developments and Class Counsel's petition for an award of attorneys' fees and expenses and service awards to the Class Representatives. Your rights and options with regard to the Ortho Settlement and the Proposed Distribution – **and the deadlines to exercise them** – are explained in this Notice.

Please visit www.bloodreagentsantitrustlitigation.com or call 1-885-231-9423 for more information about this lawsuit, including access to court documents about the lawsuit, the prior settlement, and this settlement.

DO NOT CONTACT THE COURT OR DEFENDANTS IF YOU HAVE QUESTIONS REGARDING THIS NOTICE

PART 1: GENERAL INFORMATION

WHAT IS THIS NOTICE ABOUT?

1.1 Why did I receive this Notice?

You received this Notice because you have been identified as a direct purchaser of Traditional Blood Reagents from Ortho and/or Immucor (collectively, the "Defendants") or their subsidiaries. The Court authorized this Notice because you have a right to know about the Ortho Settlement and the Proposed Distribution described below, and your options regarding these matters. This Notice explains the lawsuit, the Ortho Settlement, and your legal rights and options with respect to the Ortho Settlement and the Proposed Distribution.

The Court in charge of this case is the United States District Court for the Eastern District of Pennsylvania, Judge Jan E. DuBois. This case is known as *In re: Blood Reagents Antitrust Litigation*, MDL No. 2081 and 09-MD-2081. The direct purchasers of Traditional Blood Reagents who are named in the lawsuit are the Plaintiffs and are also called the Class Representatives.

1.2 What is the lawsuit about?

This lawsuit was filed by F. Baragaño Pharmaceuticals, Inc.; Community Medical Center Health Care System; Professional Resources Management of Crenshaw LLC d/b/a Crenshaw Community Hospital; Douglas County Hospital; Health Network Laboratories, L.P.; Larkin Community Hospital; Legacy Health System; Mary Hitchcock Memorial Hospital, Inc.; Regional Medical Center Board d/b/a Northeast Alabama Regional Medical Center; Hospital Sisters Health System (including Sacred Heart Hospital of the Hospital Sisters of the Third Order of St. Francis, St. Anthony's Memorial Hospital, of the Hospital Sisters of the Third Order of St. Francis, St. Elizabeth's Hospital of the Hospital Sisters of the Third Order of St. Francis, St. Francis Hospital of the Hospital Sisters of the Third Order of St. Francis, St. John's Hospital of the Hospital Sisters of the Third Order of St. Francis, St. Joseph's Hospital, Breese, of the Hospital Sisters of the Third Order of St. Francis, St. Joseph's Hospital of the Hospital Sisters of the Third Order of St. Francis (Chippewa Falls), St. Joseph's Hospital, of the Hospital Sisters of the Third Order of St. Francis (Highland), St. Mary's Hospital Medical Center of Green Bay, Inc., St. Mary's Hospital, Streator, of the Hospital Sisters of the Third Order of St. Francis, St. Mary's Hospital, Decatur, of the Hospital Sisters of the Third Order of St. Francis, St. Nicholas Hospital of the Hospital Sisters of the Third Order of St. Francis, and St. Vincent Hospital of the Hospital Sisters of the Third Order of St. Francis); Schuylkill Medical Center (including Schuylkill Medical Center - East Norwegian Street and Schuylkill Medical Center - South Jackson Street); and Warren General Hospital (collectively, "Plaintiffs" or "Class Representatives") individually and as representatives of all persons in the United States who purchased Traditional Blood Reagents directly from the Defendants. The lawsuit asserts that, as a result of Defendants' alleged conduct, the prices paid for Traditional Blood Reagents were higher than they otherwise would have been. Plaintiffs seek to recover three times the actual damages that they allege Defendants' conduct caused, as well as attorneys' fees and costs. Defendants have denied Plaintiffs' allegations of price fixing. Defendants have also denied that they are liable for any damages, attorneys' fees, or costs. The Court found that Plaintiffs have submitted sufficient evidence in opposition to summary judgment to allow their claims regarding Defendants' Traditional Blood Reagents price increases in 2001 to proceed to trial against the remaining defendant, Ortho. However, the Court also concluded that Plaintiffs did not have sufficient evidence to allow claims regarding Traditional Blood Reagents price increases in 2005 and 2008 to move forward to trial.

1.3 What is a class action lawsuit?

In a class action, people or entities called class representatives sue on behalf of people or entities that have similar claims. All these entities make up the class and are called class members. The Court then resolves the issues for all class members in a single proceeding, except for those who exclude themselves from the class.

1.4 What is the current status of the lawsuit?

Several lawsuits were originally filed beginning in May 2009, and the cases were consolidated before Judge DuBois in the Eastern District of Pennsylvania. The Court certified this lawsuit as a class action on August 22, 2012 for all purposes, including trial and any future settlements, and appointed the named Plaintiffs and the law firm of Spector Roseman & Kodroff, PC to represent the class. On October 25, 2012, the Third Circuit Court of Appeals accepted Ortho's appeal of the District Court's class certification decision, and on April 8, 2015, the Third Circuit vacated the District Court's decision because it relied, in part, on a Third Circuit decision that the Supreme Court reversed in 2013. On remand from the Third Circuit, the District Court re-certified the lawsuit as a class action on October 19, 2015. Notice of the Court's decision to certify the Class was provided in early 2016.

Plaintiffs previously reached a settlement with Immucor in the amount of \$22,000,000 on January 11, 2012, which was granted final approval by the Court on September 6, 2012. As a result of this settlement, Immucor was dismissed from the case. Notice was provided about the Immucor settlement in 2012; copies of those notices are available at www.bloodreagentsantitrustlitigation.com or by calling 1-885-231-9423. More information regarding the proposed distribution of the funds from that settlement can be found in Part 3 below.

The Court has not resolved the merits of all of Plaintiffs' claims, or determined whether Plaintiffs' or Ortho's contentions are true. In July 2017, the Court granted in part and denied in part Ortho's motion for summary judgment. It dismissed Plaintiffs' claims as to the 2005 and 2008 price increases for Traditional Blood Reagents, but it found that Plaintiffs offered

sufficient evidence regarding Defendants' alleged conspiracy to fix prices starting in 2001 for Traditional Blood Reagents 2001 to allow that aspect of their claims to proceed to trial against Ortho.

As described in Part 2, subsequent to the Court's decision, on the eve of trial, Plaintiffs reached a settlement with Ortho to end the litigation.

1.5 What is the case caption?

The caption (or title) of the lawsuit is provided here. You need to include the caption with any objection you file to the Ortho Settlement Agreement or the Proposed Distribution.

**IN THE UNITED STATES DISTRICT COURT
FOR THE EASTERN DISTRICT OF PENNSYLVANIA**

IN RE: BLOOD REAGENTS ANTITRUST LITIGATION
THIS DOCUMENT RELATES TO ALL ACTIONS

MDL Docket No. 09-2081

HON. JAN E. DUBOIS

THIS NOTICE IS NOT TO BE UNDERSTOOD AS AN EXPRESSION OF ANY OPINION BY THE COURT AS TO THE MERITS OF ANY OF THE CLAIMS OR DEFENSES ASSERTED BY PLAINTIFFS OR DEFENDANTS.

PART 2: THE ORTHO SETTLEMENT

YOUR LEGAL RIGHTS AND OPTIONS WITH RESPECT TO THE ORTHO SETTLEMENT ARE DESCRIBED IN THIS SECTION	
YOU ARE A MEMBER OF THE CLASS IF YOU DID NOT EXCLUDE YOURSELF PRIOR TO APRIL 6, 2016	If you did not exclude yourself prior to April 6, 2016, you are a member of the Class. Your interests will be represented by the Class Representatives and Class Counsel listed below. As a member of the Class, you will be bound by any judgment dismissing the lawsuit against Ortho, and you will not be able to file or maintain your own lawsuit against Ortho regarding the subject of this lawsuit. By remaining in the Class, you are eligible to receive a share of the Ortho Settlement amount once it is paid out, after payment for attorneys' fees, costs and other expenses as approved by the Court.
YOU ARE NOT A MEMBER OF THE CLASS IF YOU EXCLUDED YOURSELF FROM THE CLASS PRIOR TO APRIL 6, 2016	You previously had the right to exclude yourself from the Class. Notice was sent in February 2016 and published in two editions of the <i>AABB SmartBrief</i> e-bulletin in March 2016. If you had excluded yourself from the Class, you would not have been bound by the Ortho Settlement and would not be entitled to receive any money from the Ortho Settlement. Excluding yourself from the Class would have had no effect on your rights with respect to the prior settlement with Immucor. Plaintiffs and Ortho agree that no members of the Class asked to be excluded.

HIRE YOUR OWN LAWYER	You may, but are not required to, hire your own lawyer at your own expense to advise you of your rights under the Ortho Settlement. You may also, but are not required to, enter an appearance in the lawsuit through your attorney.
OBJECT TO THE ORTHO SETTLEMENT	Because you did not previously exclude yourself from the Class, you may write to the Court to object to the terms of the Ortho Settlement, as described below.

2.1 The Proposed Settlement with Ortho.

Plaintiffs have agreed with Ortho to settle the lawsuit on behalf of the Class. The proposed settlement is only with Ortho. Defendant Immucor was previously dismissed as a result of its prior settlement.

The settlement with Ortho provides that Ortho will pay \$19.5 million.

Class Counsel believe that the Ortho settlement is fair and in the best interests of the Class Members.

2.2 How do I know if I am a member of the Class?

The Class includes all persons or entities that purchased Traditional Blood Reagents in the United States during the period November 4, 2000 through October 19, 2015 directly from a Defendant.

Even if you meet these requirements, you are not a member of the Class if you are (a) a federal governmental entity, (b) a Defendant or a Defendant’s parent, subsidiary, or affiliate, or (c) you excluded yourself from the Class prior to April 6, 2016.

2.3 Will I receive money from the Ortho Settlement?

As described in Part 3 below, Class Counsel will ask the Court to distribute the funds from the Ortho Settlement (and the Immucor settlement). Except as provided elsewhere in this Notice, it is Class Counsel’s intention to hold the funds received in an interest-bearing account until the Court orders the funds to be distributed. Class Counsel will also be asking for an award of attorneys’ fees, reimbursement of litigation expenses, and service awards for Class Representatives for their service to the Class and the Immucor settlement class. As further described in Part 3 below, Class Counsel will file with the Court a plan of distribution of the settlement funds, after reduction for any court-approved attorneys’ fees, expense reimbursements, or service awards to the Class Representatives.

2.4 The Settlement Hearing and objecting to the Ortho Settlement.

The Court will hold a hearing on October 24, 2018 at 2:00 p.m. at the James A. Byrne United States Courthouse, 601 Market Street, Philadelphia, PA 19106, Courtroom 12-B, to consider whether the Ortho Settlement is fair and should be approved. The Court may also consider whether to approve Plaintiffs’ Proposed Distribution of the settlement funds as described in Part 3 below. The hearing may be continued or rescheduled without further notice.

Because you did not exclude yourself from the Class prior to April 6, 2016, you may object to the terms of the Ortho Settlement Agreement. Your objection must be in writing, include the caption of this litigation (provided on page 3 of this Notice), state the nature and grounds for your objection, be signed by you, and be **filed no later than September 27, 2018** with the Clerk of Court, United States District Court for the Eastern District of Pennsylvania, James A. Byrne United States Courthouse, 601 Market Street, Philadelphia, PA 19106, with copies mailed to Class Counsel (address provided in Section 2.5 below). If you do not object to the Ortho Settlement or Plaintiffs’ Proposed Distribution of the settlement funds (*see* Section 3.3 below), you do not need to appear at the hearing or take any other action at this time.

THE LAWYERS REPRESENTING THE CLASS

2.5 Do I have a lawyer in this case?

The Court appointed the following law firm to represent the Class:

Eugene A. Spector
Jeffrey J. Corrigan
Rachel E. Kopp
Jeffrey L. Spector
Len A. Fisher
SPECTOR ROSEMAN &
KODROFF, P.C.
1818 Market Street, Ste. 2500
Philadelphia, PA 19103
Tel: (215) 496-0300
Email: espector@srkattorneys.com
jcorrigan@srkattorneys.com
rkopp@srkattorneys.com
jspector@srkattorneys.com
lfisher@srkattorneys.com

This law firm is called Class Counsel. You will not be personally charged for the services of these attorneys in litigating this case. If you want to be represented by your own lawyer, you may hire one at your own expense. You have the right to enter an appearance in the case through your lawyer if you wish.

If you have questions concerning this Notice or the lawsuit, you may contact the law firm listed above.

2.6 *How will the lawyers be paid?*

Attorneys for the Class are litigating this case on a completely contingent fee basis, meaning that you are not personally responsible for the attorneys' fees, costs, or expenses in the case. As described below in Part 3, Class Counsel intend to ask the Court for attorneys' fees and reimbursement of litigation expenses from the Ortho Settlement and the earlier Immucor settlement. The Court can approve or deny any such a request.

2.7 *May I enter an appearance in the litigation through an attorney at my own expense?*

You may, but do not have to, enter an appearance in the lawsuit through an attorney at your own expense.

TAKING NO ACTION

2.8 *What happens if I do nothing at all?*

If you are a member of the Class and you choose to take no action, your interests as a member of the Class will be represented by Plaintiffs and Class Counsel and you will be bound by any decision or judgment entered by the Court with regard to the Ortho Settlement. You will not be able to start or continue with a lawsuit against Ortho regarding the claims described herein. If the Ortho Settlement is approved by the Court, you will be entitled to submit evidence of your qualifying Traditional Blood Reagents purchases in order to potentially recover any overcharges you may have paid. As a member of the Class, you will not be personally responsible for attorneys' fees, costs or litigation expenses; any attorneys' fees, costs and expenses will be awarded by the Court, and paid out of the total recovery, as described in Part 3.

PART 3: DISTRIBUTION OF THE SETTLEMENT FUNDS

3.1 *What settlement funds are to be distributed?*

Plaintiffs in this case previously reached a settlement with Immucor for \$22,000,000. With respect to that settlement, notice was mailed to potential class members, was published in the *AABB News*, and was made available at www.bloodreagentsantitrustlitigation.com. Class Counsel have not previously asked the Court to distribute any of the funds from the prior settlement to settlement class members and the settlement funds are being held in an interest-bearing account. If the Court approves the Ortho Settlement, Class Counsel will now ask the Court to distribute the funds from both settlements to members of the Class, after deduction of attorneys' fees, litigation expenses and any service awards to Class Representatives.

The funds from both settlements in the litigation (that is, the Immucor and Ortho Settlements), including any accrued interest, will be combined in a single **Combined Settlement Fund**. Any entity that is a member of the Immucor Settlement Class is also a Member of the Class and, upon submission of a valid claim, may be eligible to receive a portion of the Combined Settlement Fund.

3.2 How do I know if I am a member of the Class?

As described in Section 2.2 above, this Class includes all persons or entities that purchased Traditional Blood Reagents in the United States during the period November 4, 2000 through October 19, 2015 directly from Ortho or Immucor that did not choose to exclude themselves. The Class also includes any entity that is a member of the Immucor Settlement Class. Because no entity asked to be excluded from the Class prior to the deadline, if you previously excluded yourself from the Immucor settlement class, you are still be a member of the Class.

3.3 How will the settlement funds be distributed?

The substantial majority of the Net Combined Settlement Fund (the Combined Settlement Fund less any Court-awarded attorneys' fees, expenses, and service awards) will be distributed pro-rata in accordance with each Class Member's Traditional Blood Reagents purchases from January 1, 2001 through December 31, 2004 (the "Damages Period"). The Court's decisions (a) not to allow claims based on the 2005 and 2008 price increases to proceed to trial and (b) to grant Ortho's *Daubert* motion, have at least substantially diminished, if not eliminated, the value of claims after this Damages Period. Each Class Member that files a timely claim will be allocated a share of the funds available for distribution, such that its share will be in proportion to the total of all Claimants' Traditional Blood Reagents purchases during the Damages Period, with a minimum guaranteed distribution to each such Claimant of \$250. Class Counsel anticipate using Defendants' transactional data produced in the litigation to provide Class Members a proposed calculation of their Traditional Blood Reagents purchases during the Damages Period. Class Members will have the option of accepting this calculation, or alternatively providing their own calculation of purchases during the Damages Period (with supporting documentation), which will then be subject to review by the claims administrator.

If a Class Member opted out of the Immucor settlement, its purchases during the Damages Period will be reduced accordingly. Because approximately 53% of the Combined Settlement Fund is attributable to the Immucor Settlement, if a Class Member opted out of the Immucor settlement, its purchases would be valued at approximately \$0.47 (i.e., \$1 minus \$0.53) on the dollar.

The remainder of the Net Combined Settlement Fund will be distributed to Class Members who only purchased Traditional Blood Reagents directly from a Defendant from January 1, 2005 through April 30, 2009. The Immucor settlement and the Class specified class periods extending after the Damages Period, with the Immucor Settlement Class including purchases through February 23, 2012 and the Class including purchases through October 19, 2015. Thus, the certified classes include some entities that only purchased Traditional Blood Reagents after 2004 (and not during the Damages Period). Subsequent events in the litigation, however, have substantially diminished the value of claims after the Damages Period. First, the Court's summary judgment decision dismissed claims based upon the 2005 and 2008 price increases. The Court later concluded, in granting Ortho's *Daubert* motion, that Plaintiffs' expert's testimony did not provide a reliable basis to estimate any damages from the 2001 price increase that may have continued after 2004. Nevertheless, Class Counsel believe it is appropriate to allocate some recovery based on purchases for the period January 1, 2005 through and including April 30, 2009, to reflect the release provided by these Class Members and Plaintiffs' expert's opinion that, to the extent damages from the 2001 price increase did continue, they would have stopped at that point. Accordingly, each Class Member who purchased TBR from January 1, 2005 through and including April 30, 2009, but not during the Damages Period, will receive \$250.

Class Counsel will file briefs and material in support of their Distribution Plan by **September 12, 2018**, including a sample claim form. A copy of that material will be posted on www.bloodreagentsantitrustlitigation.com or can be obtained by calling 1-855-231-9423. Once the Court grants final approval to the Ortho Settlement and the Distribution Plan, the Claims Administrator will distribute claim forms to the members of the Class. The distribution will take place as soon as practicable after review, determination, and audit of the Claim Forms by the Claims Administrator and approval by the Court of the Claims Administrator's recommendations as to the specific amounts to be paid to claimants.

3.4 *How will the lawyers be paid?*

Since they filed this case, the attorneys representing the Class and the Immucor Settlement Class have not received any payment for their services in prosecuting the lawsuit, nor have they been reimbursed for any out-of-pocket expenses. Consistent with disclosures in the prior notices, the Court previously approved payments totaling approximately \$2.5 million from the Immucor settlement fund to cover ongoing pretrial litigation expenses.

If the Court approves the proposed Ortho Settlement, Class Counsel will ask the Court to award attorneys' fees of up to one-third of the Combined Settlement Fund, plus reimbursement of expenses that they incurred in the litigation and administering the settlement funds (not to exceed \$2.75 million). Class Counsel will file their petition for attorneys' fees and reimbursement of expenses with the Court by **September 12, 2018**. A copy of the petition will be posted on www.bloodreagentsantitrustlitigation.com or can be obtained by calling 1-855-231-9423.

Any attorneys' fees and reimbursement of litigation expenses will be awarded only as approved by the Court in amounts determined to be fair and reasonable. If you wish to object to the petition for attorneys' fees and reimbursement of litigation expenses, you may do so, but only by following the instructions in Section 3.6 below.

3.5 *Will the Plaintiffs receive anything for the time and effort they contributed to the lawsuit?*

This lawsuit was filed by Plaintiffs F. Baragaño Pharmaceuticals, Inc.; Community Medical Center Health Care System; Professional Resources Management of Crenshaw LLC d/b/a Crenshaw Community Hospital; Douglas County Hospital; Health Network Laboratories, L.P.; Larkin Community Hospital; Legacy Health System; Mary Hitchcock Memorial Hospital, Inc.; Regional Medical Center Board d/b/a Northeast Alabama Regional Medical Center; Hospital Sisters Health System (comprising Sacred Heart Hospital of the Hospital Sisters of the Third Order of St. Francis, St. Anthony's Memorial Hospital, of the Hospital Sisters of the Third Order of St. Francis, St. Elizabeth's Hospital of the Hospital Sisters of the Third Order of St. Francis, St. Francis Hospital of the Hospital Sisters of the Third Order of St. Francis, St. John's Hospital of the Hospital Sisters of the Third Order of St. Francis, St. Joseph's Hospital, Breese, of the Hospital Sisters of the Third Order of St. Francis, St. Joseph's Hospital of the Hospital Sisters of the Third Order of St. Francis (Chippewa Falls), St. Joseph's Hospital, of the Hospital Sisters of the Third Order of St. Francis (Highland), St. Mary's Hospital Medical Center of Green Bay, Inc., St. Mary's Hospital, Streator, of the Hospital Sisters of the Third Order of St. Francis, St. Mary's Hospital, Decatur, of the Hospital Sisters of the Third Order of St. Francis, St. Nicholas Hospital of the Hospital Sisters of the Third Order of St. Francis, and St. Vincent Hospital of the Hospital Sisters of the Third Order of St. Francis); Schuylkill Medical Center (comprising Schuylkill Medical Center - East Norwegian Street and Schuylkill Medical Center - South Jackson Street); and Warren General Hospital, also referred to as the Class Representatives. If the Court approves the proposed Joint Settlement, Class Counsel will ask the Court to award the Class Representatives (with the Hospital Sisters and Schuylkill Medical Center plaintiffs each counting as a single Class Representative) up to \$25,000 each for the time and effort they contributed to the prosecution of this litigation. These service awards would be paid from the Combined Settlement Fund.

Any service awards will be awarded only as approved by the Court in amounts determined to be fair and reasonable. If you wish to object to the proposed service awards, you may do so, but only by following the instructions in Section 3.6 below.

3.6 *How do I object to the Distribution Plan, Class Counsel's request for attorneys' fees and reimbursement of litigation expenses, or service awards for the Class Representatives?*

If you wish to object to the proposed distribution (including the Distribution Plan, request for attorneys' fees, request for reimbursement of litigation expenses, and/or request for service awards), you must specify in writing all of your objections to the proposal and the basis for those objections, as well as: (i) the caption of this litigation (provided on page 3 of this Notice); (ii) the name, address, and telephone number of the person or entity objecting and, if represented by a lawyer, of his or her lawyer; and (iii) a statement describing any purchases of Traditional Blood Reagents you made directly from Defendants from November 4, 2000 through October 19, 2015, including the dates and amounts of such purchases.

Your objection must be **filed no later than September 27, 2018** with the Clerk of Court, United States District Court for the Eastern District of Pennsylvania, James A. Byrne United States Courthouse, 601 Market Street, Philadelphia, PA 19106, with copies mailed to Class Counsel (address provided in Section 2.5 above).

At the Settlement Hearing described in Section 2.4 above, the Court will also consider whether Class Counsel's proposed distribution (including the Distribution Plan, request for attorneys' fees, request for reimbursement of litigation expenses, and/or request for service awards) is fair and should be approved.

PART 4: GETTING MORE INFORMATION

4.1 How can I get more information?

This Notice is only a summary of the Court's decision. You may obtain more information by visiting www.bloodreagentsantitrustlitigation.com or by calling 1-855-231-9423.

**PLEASE DO NOT CONTACT THE COURT, THE CLERK OF THE COURT OR DEFENDANTS.
IF YOU HAVE ANY QUESTIONS REGARDING THIS NOTICE, PLEASE DIRECT THEM
ONLY TO THE BLOOD REAGENTS ANTITRUST LITIGATION ADMINISTRATOR.**